WHO Approves Essential Medicines for Multiple Sclerosis while Obesity Drugs are Excluded

By Staff Writer

August 10, 2023

The World Health Organization (WHO) has made a significant move in global health by releasing new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc). These lists include new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions among others.

The aim? To increase access to innovative medicines that show clear clinical benefits, without stretching the health budgets of low- and middle-income countries.

With a record 85 applications considered, the updated lists now include a total of 502 medicines on the EML and 361 on the EMLc.

For the first time, medicines for the treatment of Multiple Sclerosis (MS), such as cladribine, glatiramer acetate, and rituximab have been included in the EML. These drugs can delay or slow the progression of MS, offering improved access to treatment for people living with this chronic condition. MS affects approximately 2.8 million people worldwide.
However, it’s important to note that obesity drugs including glucagon-like peptide-1 receptor agonists for weight loss, were not included in the updated EML. This decision is based on the EML’s criteria, which only includes medicines that have solid evidence for safety and efficacy.

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.